113
Views
15
CrossRef citations to date
0
Altmetric
Original Research

PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway

, , , , , , , & show all
Pages 557-566 | Published online: 12 Jan 2015

References

  • SakhraniNMPadhHOrganelle targeting: third level of drug targetingDrug Des Devel Ther20137585599
  • ParveenSMisraRSahooSKNanoparticles: a boon to drug delivery, therapeutics, diagnostics and imagingNanomedicine2012814716621703993
  • PetrosRADeSimoneJMStrategies in the design of nanoparticles for therapeutic applicationsNat Rev Drug Discov2010961562720616808
  • DavisMEZuckermanJEChoiCHEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature20104641067107020305636
  • WoodrowKACuYBoothCJSaucier-SawyerJKWoodMJSaltzmanWMIntravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNANat Mater2009852653319404239
  • ZhangJSunHMaPXHost-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene deliveryACS Nano201041049105920112968
  • GeelsPEisenhauerEBezjakAPalliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancerJ Clin Oncol2000182395240510856099
  • AcharyaSSahooSKPLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effectAdv Drug Deliv Rev20116317018320965219
  • UmanoMUechiKUriudaTTumor accumulation of epsilon-poly-lysines-based polyamines conjugated with boron clustersAppl Radiat Isot2011691765176721439838
  • TaharaKFurukawaSYamamotoHKawashimaYHybrid-modified poly(D,L-lactide-co-glycolide) nanospheres for a novel cellular drug delivery systemInt J Pharm201039231131320347023
  • DuncansonWJFigaMAHallockKZalipskySHamiltonJAWongJYTargeted binding of PLA microparticles with lipid-PEG-tethered ligandsBiomaterials2007284991499917707503
  • GrefRMinamitakeYPeracchiaMTBiodegradable long-circulating polymeric nanospheresScience1994263160016038128245
  • RyschichEHusztyGKnaebelHPHartelMBüchlerMWSchmidtJTransferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreasEur J Cancer2004401418142215177502
  • SinhaRKimGJNieSShinDMNanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug deliveryMol Cancer Ther200651909191716928810
  • TortorellaSKaragiannisTCTransferrin receptor-mediated endocytosis: a useful target for cancer therapyJ Membr Biol201424729130724573305
  • TortorellaSKaragiannisTCThe significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systemsCurr Drug Deliv20141142744324387131
  • PetreCEDittmerDPLiposomal daunorubicin as treatment for Kaposi’s sarcomaInt J Nanomedicine2007227728818019828
  • GuoLTChenBALiuRBiocompatibility assessment of polyethylene glycol-poly L-lysine-poly lactic-co-glycolic acid (PEG-PLL-PLGA) nano-particles in vitro and in vivoJ Nanosci Nanotechnol20141411024730249
  • LiuJQiuZWangSZhouLZhangSA modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activityBiomed Mater2010506500220924138
  • HaleyBFrenkelENanoparticles for drug delivery in cancer treatmentUrol Oncol200826576418190833
  • SannaVPalaNSechiMTargeted therapy using nanotechnology: focus on cancerInt J Nanomedicine2014946748324531078
  • SharmaAJainNSareenRNanocarriers for diagnosis and targeting of breast cancerBiomed Res Int2013201396082123865076
  • KimBYRutkaJTChanWCNanomedicineN Engl J Med20103632434244321158659
  • ZhangHWangCChenBWangXDaunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery systemInt J Nanomedicine2012723524222275838
  • BrandsmaMEJevnikarAMMaSRecombinant human transferrin: beyond iron binding and transportBiotechnol Adv20112923023821147210
  • DanielsTRDelgadoTRodriguezJAHelgueraGPenichetMLThe transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancerClin Immunol200612114415816904380
  • SinghMMuglerKHailooDWDifferential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinomaAppl Immunohistochem Mol Morphol20111941742321297444
  • SzwedMMatusiakALaroche-ClaryARobertJMarszalekIJozwiakZTransferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cellsToxicol In Vitro20142818719724055890
  • LaiHNakaseILacosteESinghNPSasakiTArtemisinin-transferrin conjugate retards growth of breast tumors in the ratAnticancer Res2009293807381019846912
  • FangJNakamuraHMaedaHThe EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdv Drug Deliv Rev20116313615120441782
  • FumotoSKawakamiSCombination of nanoparticles with physical stimuli toward cancer therapyBiol Pharm Bull20143721221624492718
  • KettigerHSchipanskiAWickPHuwylerJEngineered nanomaterial uptake and tissue distribution: from cell to organismInt J Nanomedicine201383255326924023514
  • PackhamGStevensonFKBodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemiaImmunology200511444144915804279
  • ElkholiRFlorosKVChipukJEThe role of BH3-only proteins in tumor cell development, signaling, and treatmentGenes Cancer2011252353721901166
  • AgarwalAMahfouzRZSharmaRKSarkarOMangrolaDMathurPPPotential biological role of poly (ADP-ribose) polymerase (PARP) in male gametesReprod Biol Endocrinol2009714319961617
  • DanialNNBCL-2 family proteins: critical checkpoints of apoptotic cell deathClin Cancer Res2007137254726318094405
  • OltersdorfTElmoreSWShoemakerARAn inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature200543567768115902208